[go: up one dir, main page]

KR870006901A - 인터로이킨-2 조성물의 제조방법 - Google Patents

인터로이킨-2 조성물의 제조방법 Download PDF

Info

Publication number
KR870006901A
KR870006901A KR870000056A KR870000056A KR870006901A KR 870006901 A KR870006901 A KR 870006901A KR 870000056 A KR870000056 A KR 870000056A KR 870000056 A KR870000056 A KR 870000056A KR 870006901 A KR870006901 A KR 870006901A
Authority
KR
South Korea
Prior art keywords
interleukin
composition
acid
adjusted
mixture
Prior art date
Application number
KR870000056A
Other languages
English (en)
Other versions
KR960012064B1 (ko
Inventor
알·대처 데이비드
가즈히로 시마
Original Assignee
요시또시 가즈오
시오노기 세이야꾸 가부시끼 가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 요시또시 가즈오, 시오노기 세이야꾸 가부시끼 가이샤 filed Critical 요시또시 가즈오
Publication of KR870006901A publication Critical patent/KR870006901A/ko
Priority to IN1142/DEL/87A priority Critical patent/IN170586B/en
Priority to CA000556062A priority patent/CA1333724C/en
Priority to JP78188A priority patent/JPS63175367A/ja
Priority to US07/141,703 priority patent/US4851957A/en
Application granted granted Critical
Publication of KR960012064B1 publication Critical patent/KR960012064B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

내용 없음.

Description

인터로이킨-2 조성물의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (5)

  1. 인터로이킨-2 조성물의 제조방법에 있어서, 1중량부의 인터로이킨-2와 1∼500중량부의 혈청알부민 및 필요하다면 약학적으로 허용 가능한 담체를 함유하는 용액에 염기를 가하여 pH 8∼11, 더욱 바람직하기로는 9∼11로 조절한 후, 즉시 산을 가하여 pH 6.1∼9로 조절하거나; 상기 용액에 산을 가하여 pH 2∼6, 더욱 바람직하기로는 2∼4로 조절한 후, 즉시 염기를 가하여 pH 6.1∼9로 조절함을 특징으로 하는 인터로이킨-2 조성물의 제조방법.
  2. 제1항에 있어서, 담체가 당 또는 당 알코올 또는 이들의 혼합물인 인터로이킨-2 조성물의 제조방법.
  3. 제1항에 있어서, 혈청 알부민이 인간 혈청 알부민 인인터로이킨-2 조성물의 제조방법.
  4. 제1항에 있어서, 용액에 계면활성제를 첨가하는 인터로이킨-2 조성물의 제조방법.
  5. 제1항에 있어서, 염기가 N-메틸글루카민, 모노에탄올아민, 디에탄올아민, 트리에탄올아민 또는 아르기닌 또는 이들의 혼합물이고, 산이 시트르산, 타르타르산, 젖산 또는 포스포르산 또는 이들의 혼합물인 인터로이킨-2 조성물의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870000056A 1986-01-07 1987-01-07 인터로이킨-2-조성물의 제조방법 KR960012064B1 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
IN1142/DEL/87A IN170586B (ko) 1987-01-07 1987-12-29
CA000556062A CA1333724C (en) 1987-01-07 1988-01-07 Safety device for communication equipment
JP78188A JPS63175367A (ja) 1987-01-07 1988-01-07 通信機器用保安装置
US07/141,703 US4851957A (en) 1987-01-07 1988-01-07 Safety device for telecommunication equipment

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP1846 1986-01-07
JP61001846A JPH0645551B2 (ja) 1986-01-07 1986-01-07 インタ−ロイキン−２組成物
JP1846/1986 1986-01-07

Publications (2)

Publication Number Publication Date
KR870006901A true KR870006901A (ko) 1987-08-13
KR960012064B1 KR960012064B1 (ko) 1996-09-12

Family

ID=11512913

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870000056A KR960012064B1 (ko) 1986-01-07 1987-01-07 인터로이킨-2-조성물의 제조방법

Country Status (8)

Country Link
EP (1) EP0229016B1 (ko)
JP (1) JPH0645551B2 (ko)
KR (1) KR960012064B1 (ko)
AT (1) ATE82857T1 (ko)
CA (1) CA1288340C (ko)
DE (2) DE229016T1 (ko)
ES (1) ES2043609T3 (ko)
GR (1) GR3006807T3 (ko)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
DE3621828A1 (de) * 1986-06-28 1988-01-14 Biotest Pharma Gmbh Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
EP0284249A1 (en) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
JPH0676332B2 (ja) * 1988-03-09 1994-09-28 大塚製薬株式会社 インターロイキン‐１βの安定化組成物
JP2799483B2 (ja) * 1988-03-09 1998-09-17 大塚製薬株式会社 インターロイキン−１β組成物の安定化方法
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
ZA902663B (en) * 1989-04-07 1991-12-24 Syntex Inc Interleukin-1 formulation
JP2818834B2 (ja) * 1991-08-12 1998-10-30 大塚製薬株式会社 ＩＬ−１α安定化医薬製剤
FR2684878B1 (fr) * 1991-12-12 1994-02-11 Roussel Uclaf Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6008188A (en) * 1994-05-06 1999-12-28 Kanebo Limited Cytokine potentiator and pharmaceutical formulation for cytokine administration
AU9280798A (en) * 1997-10-03 1999-04-27 Shionogi & Co., Ltd. Process for freeze-drying proteins
WO2001077137A1 (en) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
DE60031999T2 (de) * 1999-10-04 2007-06-06 Novartis Vaccines and Diagnostics, Inc., Emeryville Stabilisierte flüssige polypeptid-haltige pharmazeutische zusammensetzungen
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
CA2512681A1 (en) 2003-01-08 2004-07-29 Chiron Corporation Stabilized aqueous compositions comprising tissue factor pathway inhibitor (tfpi) or tissue factor pathway inhibitor variant
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
DE10348550A1 (de) * 2003-10-20 2005-06-16 Hexal Biotech Forschungsgmbh Stabile wässrige G-CSF-haltige Zusammensetzungen
CN101837119B (zh) * 2010-05-19 2012-07-04 山东东阿阿胶股份有限公司 白介素-11半成品溶液的制备方法及其产品

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
EP0211835B1 (en) * 1984-03-28 1990-01-03 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
JPS60222424A (ja) * 1985-01-25 1985-11-07 Takeda Chem Ind Ltd インタ−ロイキン−２組成物
EP0158487B1 (en) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
US4816440A (en) * 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection

Also Published As

Publication number Publication date
GR3006807T3 (ko) 1993-06-30
DE3782828T2 (de) 1993-04-29
EP0229016A3 (en) 1988-10-05
DE229016T1 (de) 1988-01-14
DE3782828D1 (de) 1993-01-14
EP0229016A2 (en) 1987-07-15
JPS62164631A (ja) 1987-07-21
KR960012064B1 (ko) 1996-09-12
EP0229016B1 (en) 1992-12-02
CA1288340C (en) 1991-09-03
ATE82857T1 (de) 1992-12-15
ES2043609T3 (es) 1994-01-01
JPH0645551B2 (ja) 1994-06-15

Similar Documents

Publication Publication Date Title
KR870006901A (ko) 인터로이킨-2 조성물의 제조방법
SE8702907D0 (sv) Stable pharmaceutical preparation containing granulocyte colony stimulating factor and process for producing the same
MY101553A (en) New pharmaceutical preparations with extended release.
ATE53038T1 (de) Inositoltriphosphat, verfahren zu seiner herstellung und dieses enthaltende zubereitung.
DE3766200D1 (de) L-dopa enthaltendes arzneimittel.
IS1565B (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
AU1141288A (en) Production of proteins in active forms
DE3770830D1 (de) Zubereitung von pregnanolol in einer stabilen oel-in-wasser-emulsion.
FI940696A0 (fi) Uudet pyratsiinijohdannaiset, niiden valmistus ja käyttö
SE7904118L (sv) Sett att framstella en urokinaskomposition
DE3866408D1 (de) Selbstklebende vorrichtung zur transdermalen verabreichung eines wirkstoffs.
KR880013572A (ko) 인슐린 및 인슐린 유도체의 혼합결정체, 이의 제조방법, 이를 함유하는 약제 및 이의 용도
ES2038969T3 (es) Procedimiento para la renaturalizacion de proteinas.
NO172188C (no) Fremstilling av pertussis-toksin ved dyrkning av bordetella pertussi
KR880003621A (ko) 의약 제제물
IL82925A0 (en) Tetrahydrobenzothiazoles,their preparation and pharmaceutical compositions containing them
KR880012226A (ko) 외 용 제
KR880013564A (ko) 마두라마이신의 공급 예비혼합 조성물 및 이에 대한 제조방법
DE58908775D1 (de) 2-Halogensubstituierte N-Indolylethyl-sulfonsäureamide, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln.
ES8706815A1 (es) Procedimiento de preparar bebidas alcoholicas que tiene un alto contenido de proteinas
KR880007005A (ko) 표고균사체의 인공배양과 음료화 방법
SE9002508D0 (sv) Asymmetric synthesis of furo (3,4-c) pyridine derivatives
ATE71529T1 (de) Pharmazeutische praeparate zur transdermalen applikation von heparin.
KR860000073A (ko) 기계적 응력에 대해 안정화된 수성인슐린 제제의 제조방법
KR870005987A (ko) N-[[(s)-4-옥소-2-아제티디닐]-카르보닐]-l-히스티딜-l-프롤린아미드의 신규 결정의 제조방법

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19870107

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19911113

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19870107

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19950320

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 19950719

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19950320

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2001 Appeal

Appeal kind category: Appeal against decision to decline refusal

Decision date: 19960731

Appeal identifier: 1995201001923

Request date: 19950823

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

Comment text: Decision on Publication of Application

Patent event code: PG16051S01I

Patent event date: 19960822

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19961125

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19961227

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19961227

End annual number: 3

Start annual number: 1

PR1001 Payment of annual fee

Payment date: 19990413

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20000710

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20010713

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20020712

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20030903

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20040719

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20050905

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20060908

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20060908

Start annual number: 11

End annual number: 11

EXPY Expiration of term
PC1801 Expiration of term